$BCML

BayCom Corp (BCML): Submission of Matters to a Vote of Security Holders

BayCom Corp (BCML) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. BAYCOM CORP_June 16, 2026 0001730984 false 0001730984 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest ev

Original reporting
Published Jun 17, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BCML
Neutral
high confidence
Mentioned
$BCML
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCMLNeutralLow
01

Why it matters

The disclosure confirms shareholder approval of the slate of directors, advisory executive compensation, and ratification of Baker Tilly US, LLP as independent auditor for the year ending Dec. 31, 2026.

02

Market read

Primarily governance/administrative confirmation; not a new earnings, guidance, or transaction catalyst.

03

What to watch

Traders may instead focus on whether the elected board composition or auditor change affects near-term audit/controls risk—this filing alone does not indicate any problem.

Relevance 6/10Novelty 2/10Timing: after-hours/filing day (June 17, 2026)

Background

This is an SEC Form 8-K (Item 5.07) summarizing final results from BayCom Corp’s June 16, 2026 annual shareholder meeting.

Company-level read

Ticker impact

$BCMLNeutralHigh confidence
Context

BayCom Corp filed an 8-K reporting final shareholder voting results for director elections, say-on-pay, and auditor ratification on June 16, 2026.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless investors were expecting a contested outcome.

Evidence & confidence

The filing discloses standard proxy-meeting outcomes (directors elected, advisory compensation approved, Baker Tilly ratified) without new financial guidance, transactions, or enforcement actions.

Market effects

Minimal; governance vote outcomes are company-specific and not a sector catalyst.

Minimal; no regional macro or banking-industry shock described.

Minimal; no cross-border transaction or global regulatory development mentioned.

Counterpoint

If there had been a close or contested vote, it could signal governance dissatisfaction; however, the article provides no such context beyond the vote tallies.

Key entities

  • BayCom Corp

    Subject of the 8-K; reported final voting results for director election, say-on-pay, and auditor ratification.

  • Baker Tilly US, LLP

    Independent registered public accounting firm ratified by shareholders for 2026.

Related articles

$BCMLMed

BayCom Corp Announces 2026 Second Quarter Results

BayCom Corp (BCML) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bcml-20260723xex99d1.htm EX-99.1 ​ Exhibit 99.1 Press Release ​ BayCom Corp Announces 2026 Second Quarter Results ​ WALNUT CREEK, CA , July 23, 2026—(Business Wire) BayCom Corp (“BayCom” or the “Company”) (NASDAQ: BCML), the holding company for United Business Bank (the

$AIBMedAI 9/10

BlockchAIn Digital Infrastructure Says Nebius Prepayment Funds $800M Data Center Build

BlockchAIn Digital Infrastructure (AIB) announced an $800M data center build funded by Nebius prepayments. The project, expected to start cash flows in Q4 2027, will have 50 MW capacity. AIB aims for 90% EBITDA margins and prefers investments at the project level, with no conversion into common stock. The company has additional sites totaling 280 MW of potential capacity.

$XFORMedAI 8/10

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (XFOR) secured up to $150M in debt financing from K2 HealthVentures, refinancing existing debt and providing additional capital. The initial $80M tranche was used to repay $75M in outstanding debt. The new agreement offers extended repayment terms and supports clinical development, including the potential commercial launch of mavorixafor for chronic neutropenia.

$AVOMed

Mission Produce unveils five-year targets, $100M buyback, aims to double sales and triple EBITDA by 2035

Mission Produce announced a five-year plan with mid-single-digit organic sales growth, 300bps margin expansion, and 2035 targets to double sales to $4B and triple Adjusted EBITDA to $450M. The company reaffirmed fiscal 2H26 Adjusted EBITDA outlook of $84–88M and Q426 Adjusted EBITDA of $52–55M. It also launched a $100M share repurchase program, with 290,994 shares repurchased at an average price of $12.94.